2bind GmbH and Assay.Works Join Forces to Expand Drug Discovery Services
October 2018 – 2bind GmbH and Assay.Works announce a strategic partnership to significantly enhance their joint offerings for pharmaceutical and biotech customers in drug discovery research. The agreement includes shared laboratory space at the BioPark Regensburg, fostering seamless collaboration, scientific exchange, and operational efficiencies. This partnership grants Assay.Works access to 2bind’s extensive experience in biophysical analysis services, including molecular interaction studies crucial for hit identification, validation, and characterization. In turn, 2bind’s clients benefit from Assay.Works’ broad range of cell-based and biochemical assays, along with its automated high-throughput screening (HTS) capabilities. ”We are excited to collaborate with 2bind and offer our clients additional biophysical assays for characterizing hit and lead compounds,” said Dr. Ralf Schwandner, Founder and Managing Director of Assay.Works. This collaboration strengthens both companies’ ability to serve the drug discovery market by combining expertise in functional bioassays, molecular interaction studies, and HTS.
